Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open RECLAIM-DCP long-term open-label study of deutetrabenazine in pediatric dyskinetic cerebral palsy
MOH_2020-02-09_008688Phase 3Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deutetrabenazine in cerebral palsy (CP) and dyskinesia, sponsored by Teva Pharmaceutical Industries Ltd. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
deutetrabenazine
03
Conditions
cerebral palsy (CP)dyskinesia
Beyond the preview
Go deeper on MOH_2020-02-09_008688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-09_008688.